Shares of Nurix Therapeutics (NRIX) plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.
Several prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer decreased its target to $32 from $35, although it maintained an Outperform rating on the stock.
The series of target price reductions comes as Nurix Therapeutics prepares to release its first-quarter financial results. According to FactSet Research Systems, analysts expect the company to report a loss of $0.76 per share for the quarter. The combination of lowered price targets and the anticipation of a quarterly loss appears to have dampened investor sentiment, contributing to the sharp decline in NRIX's stock price during the session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.